Biogen Agrees to Tofersen Access in July for Rapidly Advancing ALS

Biogen Agrees to Tofersen Access in July for Rapidly Advancing ALS

293310

Biogen Agrees to Tofersen Access in July for Rapidly Advancing ALS

People with very rapidly progressing familial amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene may gain early access to Biogen’s experimental therapy tofersen by mid-July, the company announced. This marks the first part of Biogen’s planned access program for tofersen, and will begin after patients initially assigned to a placebo in VALOR, the Phase 3 portion of a pivotal clinical trial (NCT02623699), complete the six-month trial period and are switched to the experimental therapy. VALOR is…

You must be logged in to read/download the full post.